Evaluation of Access to Licensed Vaccines for High-Risk Infectious Diseases: A Comprehensive Review and Interpretive Analysis of Ebola Virus Disease - Takeaways - MDSpire

Evaluation of Access to Licensed Vaccines for High-Risk Infectious Diseases: A Comprehensive Review and Interpretive Analysis of Ebola Virus Disease

  • By

  • Charlot Diepvens

  • Donovan Guttieres

  • Kim De Boeck

  • Nico Vandaele

  • Leonor Guariguata

  • Catherine Decouttere

  • January 10, 2026

  • 0 min

Share

  • 1

    Global efforts have reduced life lost to infectious diseases, but outbreaks persist due to human-animal interactions and climate change.

  • 2

    Ebola virus disease (EVD) has a high case fatality ratio, averaging 67%, but vaccination and supportive care can reduce this to approximately 25%.

  • 3

    Four EBOV vaccine regimens were licensed within five years, with Ervebo being the fastest prequalified vaccine by WHO.

  • 4

    A global stockpile of 500,000 Ervebo doses was established, but many doses have expired or been repurposed due to limited demand.

  • 5

    This review addresses post-licensure challenges in EVD vaccination, highlighting the need for improved access and timely decision-making.

Original Source(s)

Evaluation of Access to Licensed Vaccines for High-Risk Infectious Diseases: A Comprehensive Review and Interpretive Analysis of Ebola Virus Disease

  • by Charlot Diepvens, Donovan Guttieres, Kim De Boeck, Nico Vandaele, Leonor Guariguata, Catherine Decouttere

  • January 10, 2026

Related Content

AAE Revises Dental Trauma Guidance

Recommendations outline splinting, replantation timing, imaging, and long-term surveillance strategies for permanent tooth injuries.

The Ebola outbreak will lead to devastating violence against women and girls

The hantavirus is a wake-up call. Will the Trump administration answer it?